To Test? To Treat?


The New York Times' Shannon Brownlee and Jeanne Lenzer discuss physicians' "polarized views about the logic of routine testing" for cancers, particularly in light of the recent debates over the utility of prostate-specific antigen testing. "The dueling narratives of PSA testing boil down to the way each side frames the potential for harm from the disease compared with the collateral damage from the test and subsequent treatment," Brownlee and Lenzer write.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.